Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. reports developments in single cell and spatial biology, including financial results, product launches and collaborations tied to its research platforms. The company sells integrated instruments, consumables and software used by academic, translational and biopharmaceutical researchers to analyze biological systems at single-cell and spatial resolution.
Recurring updates cover platforms such as Chromium, Visium, Xenium and Atera; consumables demand; spatial whole-transcriptome analysis; research collaborations and data-generation initiatives; conference presentations; and management commentary on revenue, cash resources and outlook. Company news also reflects applications in oncology, immunology, neuroscience and other disease research areas.
10x Genomics (Nasdaq: TXG) will announce its third quarter 2022 financial results after market close on November 2, 2022. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, business developments, and future outlook. Investors can access the live audio on the company's website, with playback available for at least 45 days post-event. 10x Genomics provides advanced life science technology solutions for analyzing biological systems, with strong adoption among leading global research institutions and pharmaceutical companies.
10x Genomics (Nasdaq: TXG) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 10:35 a.m. Eastern Time. The company will engage in a fireside chat, with a live and archived webcast available on its investors' webpage. 10x Genomics, a life sciences technology leader, focuses on products that enhance understanding of biological systems. Their solutions are widely adopted by top global research institutions and pharmaceutical companies, backed by over 1,500 patents and citations in over 3,800 research papers.
10x Genomics (NASDAQ: TXG) reported a 1% decrease in revenue for Q2 2022, totaling $114.6 million, down from $115.8 million in Q2 2021. Factors included decreased demand from China, logistics issues in Europe, and foreign exchange challenges. The gross margin fell to 76%, significantly down from 96% in the previous year. Operating expenses rose 24% to $150 million, with an operating loss of $63.1 million compared to $10.3 million last year. The company revised its 2022 revenue guidance to $500-$520 million, reflecting 2%-6% growth.
10x Genomics, Inc. (NASDAQ: TXG) announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California, scheduled for August 11, 2022, at 9:00 a.m. PT. The company's management will engage in a fireside chat, which will also be accessible via webcast on the company's investor website. 10x Genomics focuses on life sciences technology, offering advanced biological analysis tools and has over 1,500 patents. Their products are widely used by leading researchers and pharmaceutical companies globally.
10x Genomics, Inc. (Nasdaq: TXG) has appointed Jim Wilbur, Ph.D., as the new Chief Commercial Officer, effective July 27, 2022. With nearly 30 years of experience in building businesses and leading commercial teams, Wilbur will enhance the company’s commercial strategy and execution. Previously at Meso Scale Discovery, he led the commercial functions and achieved significant growth. Wilbur is optimistic about 10x's potential in single cell and spatial biology and aims to drive a culture of commercial excellence.
10x Genomics, Inc. (Nasdaq: TXG) announced preliminary revenue of approximately $114.5 million for Q2 2022, marking a 1% decrease year-over-year. Geographic revenue breakdown shows Americas at $70.9 million (+8%), EMEA at $25.6 million (-11%), and APAC at $18.1 million (-15%). CEO Serge Saxonov noted that results fell short of expectations but expressed confidence in future growth. The company will provide a full financial outlook on August 8, 2022, during their earnings call.
10x Genomics (TXG) announced significant product advancements at the AGBT General Meeting, showcasing its leadership in single-cell and spatial analysis. The company introduced the Fixed RNA Profiling Kit, enabling single-cell RNA sequencing from FFPE tissues for the first time, and announced preorders for the Visium CytAssist, its first spatial instrument. Furthermore, the Xenium In Situ Analyzer is set to ship by year-end, enhancing in situ analysis capabilities. These innovations underscore TXG's commitment to advancing research in genomics and biology.
Fanatics has appointed Lydia Jett and Jonathan Mildenhall to its board of directors, bringing extensive experience from fintech, e-commerce, and marketing sectors. Jett, from SoftBank, played a crucial role in Fanatics' growth since their initial $1 billion investment in 2017. Mildenhall, former CMO of Airbnb, is noted for transforming brand strategies. Both directors will guide Fanatics in expanding its diverse portfolio, which includes licensed merchandise, digital collectibles, and online sports betting. Additionally, Fanatics released its first ESG report, highlighting its commitment to sustainability and social responsibility.
10x Genomics, Inc. (Nasdaq: TXG) reported Q1 2022 revenue of $114.5 million, an 8% increase year-over-year. The growth stemmed from higher consumables and instrument sales, particularly the Chromium X Series. However, gross margin decreased to 78% from 84%, attributed to product mix changes and rising costs. Operating expenses rose 32% to $130.8 million, leading to an operating loss of $41.7 million and a net loss of $42.4 million. The company maintains its revenue guidance of $600 million to $630 million for 2022, projecting 22% to 28% growth.
On April 26, 2022, 10x Genomics (Nasdaq: TXG) announced their participation in the BofA Securities 2022 Healthcare Conference in Las Vegas. The management team will engage in a fireside chat on May 10 at 8:40 a.m. PT. A live and archived webcast of this presentation will be accessible through the company's website. 10x Genomics specializes in innovative life science technology aimed at understanding biological systems, with their products widely used by leading research institutions and pharmaceutical companies globally.